With NP | Without NP | Total | |
---|---|---|---|
Number of patients | 100 | 109 | 209 |
Sex (%) | |||
Female | 89 (89.0) | 94 (86.2) | 183 (87.6) |
Male | 11 (11.0) | 15 (13.8) | 26 (12.4) |
Age, yrs (mean ± SD) | 40.9 ± 12.8 | 46.3 ± 14.3 | 43.7 ± 13.8 |
Ethnicity (%) | |||
Caucasian | 94 (94.0) | 99 (90.8) | 193 (92.3) |
Black | 2 (2.0) | 4 (3.7) | 6 (2.9) |
Asian | 0 | 5 (4.6) | 5 (2.4) |
Other | 4 (4.0) | 1 (0.9) | 5 (2.4) |
Disease duration, yrs (mean ± SD) | 8.6 ± 8.7 | 8.1 ± 9.1 | 8.4 ± 8.9 |
Cumulative ACR manifestations (%) | |||
Malar rash | 43 (43.0) | 40 (36.7) | 83 (39.7) |
Discoid rash | 9 (9.0) | 9 (8.3) | 18 (8.6) |
Photosensitivity | 60 (60.0) | 50 (45.9) | 110 (52.6) |
Oral/nasopharyngeal ulcers | 48 (48.0) | 31 (28.4) | 79 (37.8) |
Serositis | 33 (33.0) | 32 (29.4) | 65 (31.1) |
Arthritis | 67 (67.0) | 77 (70.6) | 144 (68.9) |
Renal disorder | 29 (29.0) | 28 (25.7) | 57 (27.3) |
Neurological disorder | 15 (15.0) | 0 (0) | 15 (7.2) |
Hematologic disorder | 68 (68.0) | 67 (61.5) | 135 (64.6) |
Immunologic disorder | 79 (79.0) | 94 (86.2) | 173 (82.8) |
Antinuclear antibody | 98 (98.0) | 108 (99.1) | 206 (98.6) |
SLEDAI score (mean ± SD) | 4.4 ± 4.7 | 3.4 ± 3.4 | 3.9 ± 4.1 |
SLICC/ACR damage index score (mean ± SD) | 1.4 ± 1.8 | 0.7 ± 1.3 | 1.0 ± 1.6 |
Medications, % | |||
Corticosteroids | 59 (59.0) | 64 (58.7) | 123 (58.9) |
Antimalarials | 73 (73.0) | 82 (75.2) | 155 (74.2) |
Immunosuppressants | 40 (40.0) | 41 (37.6) | 81 (38.7) |
Aspirin | 8 (8.00) | 17 (15.6) | 25 (12.0) |
Antidepressants | 23 (23.0) | 8 (7.3) | 31 (14.8) |
Anticonvulsants | 12 (12.0) | 0 (0.00) | 12 (5.7) |
Warfarin | 16 (16.0) | 9 (8.3) | 25 (12.0) |
Antipsychotics | 3 (3.0) | 1 (0.9) | 4 (1.9) |
SLE: systemic lupus erythematosus; ACR: American College of Rheumatology; SLEDAI: SLE Disease Activity Index; SLICC: Systemic Lupus International Collaborating Clinics.